CAR-T therapy gets TGA approval for ALL and DLBCL

CAR-T therapy tisagenlecleucel (formerly CTL019) has been approved by the TGA for use in paediatric and young adult patients up to 25 years of age with B-cell precursor acute lymphoblastic leukaemia (ALL). The therapy – marketed as Kymriah by Novartis...

CAR-T therapy tisagenlecleucel (formerly CTL019) has been approved by the TGA for use in paediatric and young adult patients up...

Medical politics

Specialists’ revenue hit by Medicare Freeze

Specialists’ revenue from a standard private outpatient consultation has fallen by almost $3 since the Medicare Freeze started in 2012, a new analysis shows. But specialists’ overall revenue from consultations has remained about the same because of increased use of...

Specialists’ revenue from a standard private outpatient consultation has fallen by almost $3 since the Medicare Freeze started in 2012,...

Blood cancers

High prices of blood cancer drugs aren’t justified by R&D costs

The high prices of new oncology drugs can’t be explained by R&D costs, with drug sales revenues being 15 times greater than the amount spent on development, a new study shows. While the pharmaceutical industry typically cites costs of up to...

The high prices of new oncology drugs can’t be explained by R&D costs, with drug sales revenues being 15 times...

Bleeding disorders

New clotting products approved for haemophilia patients

Extended half-life (EHL) recombinant Factor VIII and Factor IX will be added to the National Blood Authority list of clotting factor concentrates this year The decision by the Authority to add them to the next national tender for clotting...

Extended half-life (EHL) recombinant Factor VIII and Factor IX will be added to the National Blood Authority list of...